Blog

Early pregnancy failure is associated with fewer and defective regulatory T cell in peripheral blood

Early pregnancy failure is associated with fewer and defective regulatory T cell in peripheral blood

Highlights

A recent study published by Dr Robertson’s group reveals that women experiencing recurrent implantation failure and/or recurrent pregnancy losses have, prior to conception:

  • fewer CD4+ regulatory T cells in the peripheral blood.
  • these Treg cells have an altered phenotype with:
    • reduced suppressive competence
    • a pro-inflammatory shift
    • similarities with autoimmune conditions

Regulatory T cells (Treg cells) are key specialized immune cells that promote maternal-fetal tolerance1-2:

  • by suppressing inflammation
  • by preventing the uterus from rejecting the embryo through the secretion of factors suppressing the maternal immune response to “foreign” paternal components called antigens.
  • are involved in the uterine spiral artery remodeling required for placentation.

Treg cells can arise from the blood and be recruited within the decidua3 where they are “primed” by sex hormones and factors in the seminal fluid then sequestrated by trophoblast secretion4, or they may be generated locally (within the uterus) activated by the presence of the embryo (HLA-G expressed on the surface of the trophoblast)5. Lower Treg levels have been reported in the uterus of women with recurrent implantation failures, recurrent miscarriage6 and pregnancy complications such as pre-eclampsia.

In this study, the authors compared systemic (in peripheral blood samples) Treg cell profile of women with early pregnancy failures to women with proven fertility.

Results show that Treg cells are fewer and have an altered phenotype in early pregnancy failure (EPF) women.

  • Treg cells number was 32% lower in EPF women which may be linked to a higher rate of maturation leading to Treg cell exhaustion in the peripheral blood
  • These cells had a 20% lower expression of Foxp3 (a specific marker of Treg cells)
  • Treg cells were 34% less stable
  • Treg cells had 21% lower suppressive capacity
  • this is coupled with increased transcription of pro-inflammatory cytokine (IL-17, TNF-α, IL17A)

These changes may disrupt pregnancy tolerance and impair embryo implantation as the majority of decidual T cells originate from the peripheral blood.

Regulatory T cell assessment in the peripheral, prior to conception, may help determine the possible causes of your implantation failure or pregnancy losses.

Some immune therapies may help increase Treg cells expansion and recruitment to the decidua.

References

  1. Erlebacher, A. (2013). Mechanisms of T cell tolerance towards the allogeneic fetus. Nat. Rev. Immunol. 13, 23–33.
  2. Robertson, S.A., Care, A.S., and Moldenhauer, L.M. (2018). Regulatory T cells in embryo implantation and the immune response to pregnancy. J. Clin. Invest. 128, 4224–4235.
  3. Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol. 2008 Apr 15;180(8):5737-45.
  4. Schumacher A, Brachwitz N, Sohr S, Engeland K, Langwisch S, Dolaptchieva M, Alexander T, Taran A, Malfertheiner SF, Costa SD, Zimmermann G, Nitschke C, Volk HD, Alexander H, Gunzer M, Zenclussen AC. Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. J Immunol. 2009 May 1;182(9):5488-97.
  5. Tilburgs, T., Crespo, Á.C., van der Zwan, A., Rybalov, B., Raj, T., Stranger, B., Gardner, L., Moffett, A., and Strominger, J.L. (2015). Human HLA-G+ extravillous trophoblasts: Immune-activating cells that interact with decidual leukocytes. Proc. Natl. Acad. Sci. USA 112, 7219–7224.
  6. Granne, I., Shen, M., Rodriguez-Caro, H., Chadha, G., O’Donnell, E., Brosens, J.J., Quenby, S., Child, T., and Southcombe, J.H. (2022). Characterisation of peri-implantation endometrial Treg and identification of an altered phenotype in recurrent pregnancy loss. Mucosal Immunol. 15, 120–129.
Back to blog
We love questions

Talk to an expert

Pregmune’s fertility services experts are available to help you get started and to answer any questions you may have along the way.

Medical Disclaimer

Patients and physicians should always consult with a licensed medical professional before making any clinical decisions, including starting or discontinuing any treatment. Any information provided by Pregmune, including but not limited to the IRMA Report, AIMY Report, test results, risk estimates, supporting documentation, email communications or other related content (collectively, "Pregmune Content"), is intended for informational purposes only. This content is not medical advice and should not be used as a substitute for professional medical evaluation, diagnosis, or treatment. Pregmune Content is not a recommendation for any specific treatment plan, therapy, medication, or course of action. It is designed to support, not replace, the relationship between patients and their qualified healthcare providers. Pregmune does not provide medical care, and its reports and communications should never delay or override clinical judgment.